Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Clinuvel Gets Positive Phase III Scenesse Results | Contract Pharma

What are you searching for?

Sign in

Clinuvel Gets Positive Phase III Scenesse Results

Clinuvel Pharmaceuticals achieved positive results from a Phase III trial of Scenesse in patients with erythropoietic protoporphyria (EPP), showing that the drug has the ability to reduce and prevent painful phototoxic reactions.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clinuvel Pharmaceuticals achieved positive results from a Phase III trial of Scenesse in patients with erythropoietic protoporphyria (EPP), showing that the drug has the ability to reduce and prevent painful phototoxic reactions. EPP is characterized by intolerable pain associated with skin burns, blisters and scars when exposed to normal levels of light and sun. It is estimated that 10,000 individuals worldwide are afflicted with EPP.

Results from the study showed that Scenesse treatment significantly reduced the average daily pain severity scores experienced by EPP patients compared to placebo. Further results suggested that treatment with Scenesse allowed patients to expose their skin to sunlight and spend more time outdoors. Scenesse was well tolerated with no serious safety issues identified.

“We have shown mathematically what we already learned from anecdotal reports from our clinics. Scenesse has great potential to help those patients with a genuine medical need for protection from UV and light,” said Dr. Hank Agersborg, Clinuvel’s chief scientific officer. “Perhaps more importantly, we have again seen that the drug is safe for these patients longer-term.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters